Dermatology co Foamix mulls Nasdaq IPO
Galil Medical is developing cryotherapy treatments for cancer.
Nochi Dankner-controlled IDB Holding Corp. Ltd. (TASE:IDBH) technology holding company Elron Electronic Industries Ltd. (Pink Sheets: ELRNF; TASE: ELRN) is continuing the sell-off of assets with the sale of its full stake in cryotherapy cancer treatment developer Galil Medical Ltd.. Elron's parent company Discount Investment Corporation (TASE: DISI) and Rafael Development Corporation (RDC - owned in equal shares by Elron and Rafael Advanced Defense Systems Ltd.) are also selling their shares in the company. They are selling their aggregate stake in Galil Medical to its other shareholders for $1.33 million altogether.
Galil Medical is currently raising $6.4 million from its shareholders, including Elron, Discount Investment, and RDC. Galil Medical will convert existing debt owed to the three into senior shares. When the fundraising is complete, Elron will own 8.6% of Galil Medical, Discount Investment will own 9.2%, and RDC will own 12.34%.
According to Galil Medical, its other shareholders are US healthcare venture capital firms Thomas, McNerney & Partners, Investor Growth Capital, and Vertical Group.
Galil Medical was founded in 1997 on the basis of technology developed at Rafael and commercialized through RDC, and is considered a promising start-up.
If within two years, Galil Medical is sold to, or merged with, a third party, Elron, Discount Investment, and RDC will be eligible for additional payment based on the difference between a third of the proceeds of that transaction and the $1.33 million.
Elron has already sold a number of assets in the past few months, including the intellectual property of DV3 Ltd., fabless semiconductor developers Sela Ltd. and ChipX Ltd., and its stake in Internet services provider and international calls carrier NetVision Ltd. (TASE: NTSN), a sister company. The company has put insulin pump developer Medingo Ltd., one of its core businesses, up for sale.
Elron's share closed at $8.43 in New York yesterday, and the share was unchanged today on the TASE at NIS 30.89.
Published by Globes [online], Israel business news - www.globes-online.com - on March 15, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010
You comment was recieved and soon will be published.
Load more comments
The developer of foam-based dermatology treatments is seeking underwriters.
Can-Fite Biopharma raises $5m
The proceeds will finance clinical trials for psoriasis, glaucoma, and liver cancer treatments.
Teva switching Copaxone users to new dosage
"Bloomberg": Teva has switched 8.7% of Copaxone's multiple sclerosis patients to the 40 milligram dosage.
Immune Pharmaceuticals raises $11.7m on Nasdaq
The money raised will fund a Phase II trial of ulcerative colitis drug bertilmumab.
XTL Biopharma files to raise $40m on Nasdaq
XTL plans to initiate a large Phase IIb clinical trial for the treatment of Lupus.
Teva launches generic cancer drug
Brand Xeloda, made by Genentech, had $754 million in US sales in 2013.
Yelin Lapidot takes stake in Brainsway
Brainsway raised NIS 41 million in the private placement.
Barclays upgrades Teva
Barclays raised its recommendation to "Overweight" and its target price to $65.
BiolineRX raises $24m in Nasdaq offering
Three months ago, the company announced promising preliminary clinical trial results.
Teva VP Ika Abravanel resigns
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.